enGene Therapeutics Warrants
ENGNW
14 hedge funds and large institutions have $2.91M invested in enGene Therapeutics Warrants in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.43% less ownership
Funds ownership: 10.77% → 9.34% (-1.4%)
7% less funds holding
Funds holding: 15 → 14 (-1)
28% less capital invested
Capital invested by funds: $4.02M → $2.91M (-$1.11M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$82 |
| 3 |
CS
Clear Street
New York
|
+$82 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$13.4K |
| 2 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$1.92K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIS
1
FCPM III Services
Naarden,
Netherlands
| $1.73M | – | – | – |
|
|
BI
2
BVF Inc
San Francisco,
California
| $605K | – | – | – |
|
|
OFM
3
Omega Fund Management
Boston,
Massachusetts
| $193K | – | – | – |
|
|
SCM
4
Saba Capital Management
New York
| $111K | – | – | – |
|
5
Calamos Advisors
Naperville,
Illinois
| $96K | – | – | – |
|
6
D.E. Shaw & Co
New York
| $67K | – | – | – |
|
|
TCM
7
Tenor Capital Management
New York
| $33.2K | – | – | – |
|
|
BOCH
8
Blue Owl Capital Holdings
New York
| $21.7K | – | – | – |
|
|
WA
9
Whitebox Advisors
Minneapolis,
Minnesota
| $18.6K | -$1.92K | -2,333 | -7% |
|
10
State of Wisconsin Investment Board
Madison,
Wisconsin
| $15.1K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| $13.2K | +$15.7K | +19,106 | +676% |
|
|
CL
12
CSS LLC
Chicago,
Illinois
| $10.1K | – | – | – |
|
|
13
Bank of America
Charlotte,
North Carolina
| $180 | +$82 | +100 | +50% |
|
|
CS
14
Clear Street
New York
| $180 | +$82 | +100 | +50% |
|
|
WAM
15
Wolverine Asset Management
Chicago,
Illinois
| – | -$13.4K | -15,889 | Closed |
|
ENGNW Hedge Fund Activity: Q1 2025 in Review
14 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q1 2025, worth a combined $2.91M — down 28% from $4.02M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ENGNW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $15.7K. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $13.4K sold.
- 14 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q1 2025, down from 15 in Q4 2024.
- Funds reported $2.91M of enGene Therapeutics Warrants stock for Q1 2025, down 28% quarter-over-quarter.
- 0 funds opened new enGene Therapeutics Warrants positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest enGene Therapeutics Warrants buyer in Q1 2025 was UBS Group, an estimated $15.7K added.
- The largest enGene Therapeutics Warrants seller in Q1 2025 was Wolverine Asset Management, an estimated $13.4K sold.
Based on aggregated 13F filings for Q1 2025.